|
|
|
Insider
Information: |
Vessey Rupert |
Relationship: |
EVP & President, Resea... |
City: |
Summit |
State: |
NJ |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
3 |
|
Direct
Shares |
55,636 |
|
Indirect Shares
|
656 |
|
|
Direct
Value |
$2,608,801 |
|
|
Indirect Value
|
$27,401 |
|
|
Total
Shares |
56,292 |
|
|
Total
Value |
$2,636,202 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
9
|
Stock
price went up :
|
0
|
6
|
Stock
price went down : |
0
|
3
|
|
|
|
Gain/Loss Ratio : |
0.0
|
2.0
|
Percentage
Gain/Loss : |
0.0%
|
9.3%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Celgene Corp |
CELG |
|
2019-11-20 |
0 |
2019-11-20 |
0 |
Premium* |
|
Techne Corp |
TECH |
Director |
2023-10-26 |
7,885 |
2019-07-01 |
0 |
Premium* |
|
Bristol-Myers Squibb Co |
BMY |
EVP & President, Resea... |
2023-05-03 |
47,751 |
2023-05-03 |
656 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
79 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 4
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2020-11-23 |
4 |
S |
$61.34 |
$823,244 |
D/D |
(13,421) |
37,922 |
0 |
% |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2021-02-04 |
4 |
D |
$61.56 |
$73,010 |
D/D |
(1,186) |
57,223 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2021-03-01 |
4 |
D |
$61.63 |
$551,219 |
D/D |
(8,944) |
71,628 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2021-12-16 |
4 |
S |
$61.99 |
$1,196,252 |
D/D |
(19,298) |
31,960 |
0 |
% |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2020-12-31 |
4 |
D |
$62.03 |
$822,332 |
D/D |
(13,257) |
54,817 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2020-12-02 |
4 |
D |
$62.18 |
$280,183 |
D/D |
(4,506) |
42,208 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2021-12-31 |
4 |
D |
$62.35 |
$1,436,108 |
D/D |
(23,033) |
53,956 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
Pres., Research & Early Dev. |
|
2019-12-31 |
4 |
D |
$64.19 |
$507,743 |
D/D |
(7,910) |
22,868 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
Pres., Research & Early Dev. |
|
2020-02-04 |
4 |
D |
$64.29 |
$74,769 |
D/D |
(1,163) |
24,757 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2021-05-05 |
4 |
S |
$64.29 |
$1,963,802 |
D/D |
(30,546) |
45,139 |
0 |
% |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2021-05-08 |
4 |
D |
$64.44 |
$515,133 |
D/D |
(7,994) |
54,390 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2022-02-04 |
4 |
D |
$64.99 |
$85,267 |
D/D |
(1,312) |
56,237 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP & President, Research |
|
2023-03-10 |
4 |
D |
$65.71 |
$2,529,704 |
D/D |
(38,498) |
98,136 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP & President, Research |
|
2023-05-03 |
4 |
S |
$67.06 |
$3,378,818 |
D/D |
(50,385) |
47,751 |
0 |
% |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2021-07-30 |
4 |
S |
$68.01 |
$10,782,154 |
D/D |
(158,393) |
46,964 |
0 |
% |
|
CELG |
Celgene Corp |
SEE REMARKS |
|
2018-12-16 |
4 |
D |
$68.20 |
$179,639 |
D/D |
(2,634) |
7,253 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2022-03-10 |
4 |
D |
$68.42 |
$598,743 |
D/D |
(8,751) |
77,639 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2022-03-01 |
4 |
D |
$68.63 |
$707,095 |
D/D |
(10,303) |
69,284 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2022-03-16 |
4 |
S |
$69.23 |
$5,162,973 |
D/D |
(74,559) |
50,385 |
0 |
% |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2022-11-07 |
4 |
S |
$78.88 |
$3,621,381 |
D/D |
(45,910) |
57,079 |
0 |
% |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2022-12-02 |
4 |
D |
$81.13 |
$364,923 |
D/D |
(4,498) |
61,373 |
0 |
- |
|
CELG |
Celgene Corp |
SEE REMARKS |
|
2018-05-04 |
4 |
D |
$86.89 |
$133,637 |
D/D |
(1,538) |
4,537 |
0 |
- |
|
CELG |
Celgene Corp |
SEE REMARKS |
|
2019-05-02 |
4 |
D |
$95.21 |
$240,977 |
D/D |
(2,531) |
11,453 |
0 |
- |
|
CELG |
Celgene Corp |
See remarks |
|
2018-02-02 |
4 |
D |
$99.80 |
$266,765 |
D/D |
(2,673) |
2,950 |
0 |
- |
|
CELG |
Celgene Corp |
See remarks |
|
2017-06-15 |
4 |
OE |
$100.80 |
$417,358 |
D/D |
4,007 |
4,785 |
0 |
- |
|
79 Records found
|
|
Page 3 of 4 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|